Resorttrust : Cancer Intelligence Care Systems, Inc. (Consolidated Subsidiary of Resorttrust, Inc.) and Edogawa Hospital Enter Agreement to Conduct Specified Clinical Research

May 16, 2023

FOR IMME DIATE REL EASE

Canceer Intelligence Care Systems, Inc. (Consolidated Subssidiary of Resorttrust, Inc.)

and Edogawa Hospital Ennter Agreemment to Conduct Specified Cliniical Research

Resorttruust, Inc. ("thee Company") announces that it s coonsolidated subsidiary, Cancer Intellligence Care Systems, Innc. ("CICS"; President, Tetsuya Furuukawa; headdquarters, Koto-ku, Tokyo), has entered into an agreement to collaboraate in investtigator-initiated specified clinical reesearch* ("thhe Resear chh") targeting recurrent brreast cancer. CICS will cooperate in the Researchh, which is to be conductted at Edogaawa Hospitall (Edogawa-ku, Tokyo), by providing technology related to a neutron irradiation device for booron neutron capture therrapy (BNCT).

The purppose of the Research is to evaluate the safety and efficacy of BNCT in the treatmeent of breastt cancer that recurs after radiotherappy. Those paatients who have recurreent breast caancer, specifically tumorr recurrence after radiotheerapy, will be eligible.

Edogawa Hospital is equipped wiith a neutronn irradiation device that CICS has insstalled and iss developing at National Cancer Cennter Hospital. In the Ressearch, this device will be used in combination with boron compounds for BNCT developed by STELLA PHARMA COORPORATION (Chuo-k u, Osaka).

CICS suppports the intent of the Research and will provide technology related to CIICS's neutron irradiation device for BNCT. The impact this project has on the Company's consollidated businness performance will b e immaterial.

Breast caancer that recurs after radiotherapy often cannot be treated surgically, n or can it be treated with conventionaal radiotheraapy, as radi otherapy cannnot be readministered to the samee area. For this reason,, primary treatments are chemotherappy and hormmone therapyy, but these have side efffects and aree not able to treat the rooot cause thhat would completely cure the diseease. Since BNCT is a treatment method thatt selectively kills cancer cells, it is un ique in that it can be appplied to sites that have beeen irradiatedd in the past,, leading to expectations that BNCT will become a new treatmment option.

The Resoorttrust Grouup entered the medical business in 1994, beginning its membership-baased medicall club. For cancer screenning, the Grooup introducced positron emission tomography (PPET), whichh at the time was used foor research conducted at Yamanakakko Clinic. In addition to greatly contributing to the spread off PET in Japan, it has heelped to prommote research activities with university hospitals in fields suuch as image diagnosis and preemptive medicine. Today, thee Resorttrust Group is not only invoolved in screeening but is also expanding treatment solutionns, supportinng the operration of facilities provviding advanced cancerr immunotherrapy.

Based onn the brand identity of "TTog ether forr a Wonderful Life" the Resorttrust Group h as as its slogan "contributing to the agee of 100 -year life spanss (wellbeing)." Furthermore, reflecti ng the Grouup's hope to create a socciety where cancer claimms no precioous lives, it has engaged in cancer screening annd treatment. Through ouur initiatives with BNCT,, together wiith helping to create a more affluent, happy time, we hope to bring new liight to canceer treatment.

*About clinnical researchh

The term "clinical triaals," as defineed by the Cliini cal Trials Act, "refers to research to clarify thee efficacy or safety of pharmaceuticals by the u se of such pharmaceuticals in humans" (excludding those faalling under clinical trialls and other research specified by an Ordinance o f the Ministrry of Health, Labour and Welfare).

The term "specified clinical research" refers to cl inical research that is conducted under the auspices of a pharmaceutical marketing authorization holder or its special related party (i.e., subsidiary) (limited to clinical research that uses pharmaceuticals manufactured and sold or intended to be manufactured and sold by the said manufacturer or distributor) or clinical research that uses drugs not yet approved of or that are off label.

*Reference: Ministry of Health, Labour and Welfare "About Clinical Trials Act"

About BNCT

Boron neutron capture therapy (BNCT), a form of radiotherapy, is a new method of treating cancer.

When patients receive a boron agent, a boron compound (10B) accumulates in their cancer cells. The area of the tumor is then exposed to an external source of extremely low-energy neutron radiation, which while having little effect on the human body, causes the boron (10B) to capture neutrons, resulting in a reaction that causes the release of alpha rays and 7Li nuclei. BNCT is therefore a medical treatment that leverages radiation to selectively kill cancer cells.

In addition, in principle, as treatment is completed with a single neutron irradiation, expectations are for this to be a treatment that causes little damage to the body.

About the CICS neutron capture therapy device

This is an accelerator-based neutron capture therapy device developed by CICS. It produces neutrons by bombarding a lithium target with protons which are accelerated by a Radio Frequency Quadrupole (RFQ) linear accelerator. CICS-1is notable for the low level of contamination of fast neutrons, which are detrimental to the human body. The neutrons produced have a low energy level of 800keV or less, facilitating the miniaturization of the moderator used to slow the neutrons down to around 10keV, a level suitable for BNCT.